The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Adartrel     4-[2-(dipropylamino)ethyl]- 1,3...

Synonyms: Repreve, Ropitor, ropinirol, ReQuip, ropinirole, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C07564


Psychiatry related information on C07564

  • Ropinirole therapy was not associated with daytime episodes of rapid eyes movement (REM) sleep [5].
  • STUDY OBJECTIVES: Polysomnographic study evaluating the efficacy of ropinirole for the treatment of patients with restless legs syndrome (RLS) suffering from periodic leg movements in sleep (PLMS) [6].
  • The behavioral tests showed that the locomotor activities were increased significantly in the mice treated with iron-deficiency (ID) diet and 6-OHDA lesions, which were reversed by the D2/D3 agonist ropinirole [7].
  • Use of pramipexole seems to be associated with a higher risk of hallucinations than use of ropinirole when compared with placebo [2].
  • In 3 nights (adaptation, placebo, ropinirole night) sleep induction, maintenance and architecture were measured objectively by polysomnography, subjective sleep and awakening quality were assessed by self-rating scales and visual-analog scales, and objective awakening quality was evaluated by a psychometric test battery [8].

High impact information on C07564


Chemical compound and disease context of C07564


Biological context of C07564


Anatomical context of C07564


Associations of C07564 with other chemical compounds

  • Limited evidence suggests that some dopaminergic agents, such as levodopa/carbidopa, pergolide, and ropinirole, may be effective in children with RLS associated with ADHD symptoms [22].
  • The CYP1A2 inhibitor ciprofloxacin produced increases in the plasma concentrations of ropinirole when these 2 drugs were coadministered, but no interaction was seen with theophylline which, like ropinirole, is also a substrate for CYP1A2 [15].
  • In rats with a unilateral, 6-hydroxydopamine lesion of the substantia nigra, S32504 (0.0025-0.04 mg/kg, s.c.) more potently elicited contralateral rotation than S32601 [(-)-trans-3,4,4a,5,6, 10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth-[1,2-b]-1,4-oxazine (its less active enantiomer)], ropinirole, and l-3,4-dihydroxyphenylalanine (l-DOPA) [23].
  • Talipexole and the ropinirole metabolite, SKF-104557, were partial agonists at the hD4 receptor [24].
  • Ropinirole is a modern dopamine agonist with a halflife of medium extent that is highly selective for D(2)-receptors [25].

Gene context of C07564


Analytical, diagnostic and therapeutic context of C07564


  1. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., Lang, A.E. N. Engl. J. Med. (2000) [Pubmed]
  2. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Etminan, M., Gill, S., Samii, A. Drug safety : an international journal of medical toxicology and drug experience. (2003) [Pubmed]
  3. Behavioral and neurochemical effects of dopaminergic drugs in models of brain injury. Medico, M., De Vivo, S., Tomasello, C., Grech, M., Nicosia, A., Castorina, M., D'Agata, M.A., Rampello, L., Lempereur, L., Drago, F. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (2002) [Pubmed]
  4. Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Salamone, J.D., Carlson, B.B., Rios, C., Lentini, E., Correa, M., Wisniecki, A., Betz, A. Behav. Brain Res. (2005) [Pubmed]
  5. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Ferreira, J.J., Galitzky, M., Thalamas, C., Tiberge, M., Montastruc, J.L., Sampaio, C., Rascol, O. Neurology (2002) [Pubmed]
  6. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Allen, R., Becker, P.M., Bogan, R., Schmidt, M., Kushida, C.A., Fry, J.M., Poceta, J.S., Winslow, D. Sleep. (2004) [Pubmed]
  7. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. Zhao, H., Zhu, W., Pan, T., Xie, W., Zhang, A., Ondo, W.G., Le, W. J. Neurosci. Res. (2007) [Pubmed]
  8. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Saletu, B., Gruber, G., Saletu, M., Brandstätter, N., Hauer, C., Prause, W., Ritter, K., Saletu-Zyhlarz, G. Neuropsychobiology (2000) [Pubmed]
  9. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Whone, A.L., Watts, R.L., Stoessl, A.J., Davis, M., Reske, S., Nahmias, C., Lang, A.E., Rascol, O., Ribeiro, M.J., Remy, P., Poewe, W.H., Hauser, R.A., Brooks, D.J. Ann. Neurol. (2003) [Pubmed]
  10. Daytime sleepiness and other sleep disorders in Parkinson's disease. Ondo, W.G., Dat Vuong, K., Khan, H., Atassi, F., Kwak, C., Jankovic, J. Neurology (2001) [Pubmed]
  11. Pramipexole, ropinirole, and mania in Parkinson's disease. Singh, A., Althoff, R., Martineau, R.J., Jacobson, J. The American journal of psychiatry. (2005) [Pubmed]
  12. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Tel, B.C., Zeng, B.Y., Cannizzaro, C., Pearce, R.K., Rose, S., Jenner, P. Neuroscience (2002) [Pubmed]
  13. Identification of amino Acid determinants of dopamine 2 receptor synthetic agonist function. Al-Fulaij, M.A., Ren, Y., Beinborn, M., Kopin, A.S. J. Pharmacol. Exp. Ther. (2007) [Pubmed]
  14. Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist. Parker, S.G., Raval, P., Yeulet, S., Eden, R.J. Eur. J. Pharmacol. (1994) [Pubmed]
  15. Clinical pharmacokinetics of ropinirole. Kaye, C.M., Nicholls, B. Clinical pharmacokinetics. (2000) [Pubmed]
  16. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect? Chaudhuri, K.R., Pal, S., Brefel-Courbon, C. Drug safety : an international journal of medical toxicology and drug experience. (2002) [Pubmed]
  17. Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. de Mey, C., Enterling, D., Meineke, I., Yeulet, S. British journal of clinical pharmacology. (1991) [Pubmed]
  18. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Bloomer, J.C., Clarke, S.E., Chenery, R.J. Drug Metab. Dispos. (1997) [Pubmed]
  19. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Du, F., Li, R., Huang, Y., Li, X., Le, W. Eur. J. Neurosci. (2005) [Pubmed]
  20. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study. Junghanns, S., Fuhrmann, J.T., Simonis, G., Oelwein, C., Koch, R., Strasser, R.H., Reichmann, H., Storch, A. Mov. Disord. (2007) [Pubmed]
  21. The long-duration action of levodopa may be due to a postsynaptic effect. Barbato, L., Stocchi, F., Monge, A., Vacca, L., Ruggieri, S., Nordera, G., Marsden, C.D. Clinical neuropharmacology. (1997) [Pubmed]
  22. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Cortese, S., Konofal, E., Lecendreux, M., Arnulf, I., Mouren, M.C., Darra, F., Dalla Bernardina, B. Sleep. (2005) [Pubmed]
  23. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. Millan, M.J., Di Cara, B., Hill, M., Jackson, M., Joyce, J.N., Brotchie, J., McGuire, S., Crossman, A., Smith, L., Jenner, P., Gobert, A., Peglion, J.L., Brocco, M. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  24. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Coldwell, M.C., Boyfield, I., Brown, T., Hagan, J.J., Middlemiss, D.N. Br. J. Pharmacol. (1999) [Pubmed]
  25. Clinical studies with ropinirole in Parkinson's disease and RLS. Jost, W.H., Angersbach, D., Rascol, O. J. Neurol. (2006) [Pubmed]
  26. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Wynalda, M.A., Wienkers, L.C. Drug Metab. Dispos. (1997) [Pubmed]
  27. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Adler, C.H., Sethi, K.D., Hauser, R.A., Davis, T.L., Hammerstad, J.P., Bertoni, J., Taylor, R.L., Sanchez-Ramos, J., O'Brien, C.F. Neurology (1997) [Pubmed]
  28. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Sethi, K.D., O'Brien, C.F., Hammerstad, J.P., Adler, C.H., Davis, T.L., Taylor, R.L., Sanchez-Ramos, J., Bertoni, J.M., Hauser, R.A. Arch. Neurol. (1998) [Pubmed]
  29. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease? Rascol, O. J. Neural Transm. Suppl. (1999) [Pubmed]
WikiGenes - Universities